Arcadis: Feedback from conference call 3Q25. Belgian telcos: Telenet positive net adds in broadband, near ECM decision. CTP: 34k sqm lease signed in Poland. Eurocommercial Properties: Organic momentum is getting stronger. Fugro: Reasonable 3Q, challenging 4Q and beyond. Heijmans: Order book quality improves further. KPN: VodafoneZiggo guidance maintained, ECM decision near. Proximus: CPaaS peer Twilio reports strong 3Q25 results. Retail Estates: Jysk new tenant of 5 Leen Bakker B...
3Q25 figures showed overall revenues falling -12.6% to €505m well below forecasts. Thanks to solid cost control EBIT landed at €65m considerably above our €51mE and €43m CSS fcst. Following three profit warnings expectations were likely not overly challenging. Given the deep discount valuation we believe today's share price reaction is not necessarily a prelude for 2026 performance. A positive reaction will likely follow but a structural re-rating will only occur once there are clear indications...
GENFIT announces intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market GENFIT’s decision to delist from Nasdaq reflects strategic intent to simplify corporate structure and improve operational efficiencyGENFIT remains listed on the regulated market of Euronext Paris as its primary trading market Lille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); October 30, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, ...
GENFIT annonce son intention de procéder au retrait volontaire de la cotation de ses « American Depositary Shares » sur le Nasdaq Global Select Market La décision de GENFIT de retrait du Nasdaq traduit une volonté stratégique de simplifier sa structure organisationnelle et d'améliorer son efficacité opérationnelleLes actions de GENFIT restent cotées sur le marché réglementé Euronext Paris, son marché principal Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 30 octobre 2025 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique engagée dans l’amélioration...
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025 Several posters and presentations featuring new data on three ACLF programs, including G1090N (NTZ reformulation) disease model data, new real-world data and biomarker insights in cirrhosisNew Iqirvo® PBC and PSC data to be presented by partner Ipsen, underscoring its potential in rare cholestatic liver diseases Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), October 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of...
GENFIT annonce des avancées dans ses programmes ACLF lors du congrès AASLD The Liver Meeting® 2025 Plusieurs posters et présentations avec de nouvelles données relatives à trois de nos programmes dans l’ACLF, dont des données de G1090N dans des modèles précliniques, de nouvelles données en vie réelle, et des données de biomarqueurs dans la cirrhose Nouvelles données sur Iqirvo® dans la PBC et la PSC présentées par notre partenaire Ipsen, soulignant son potentiel dans le traitement des maladies hépatiques cholestatiques rares Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (S...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.